Introduction
============

MicroRNAs (miRNAs) are 20--26-nt single stranded RNAs that participatein the regulation of various biological functions in numerouseukaryotic lineages, including plants, insects, vertebrate, and mammals ^[@ref-1]--\ [@ref-3]^. More than 850 human miRNAs have been cloned and bioinformatic predictions indicate that mammalian miRNAs can regulate approximately 30% of all protein-coding genes ^[@ref-4]--\ [@ref-6]^. The expressionof many miRNAs is specific to a tissue or developmentalstage, and the miRNA expression pattern is altered during thedevelopment of several diseases ^[@ref-7],\ [@ref-8]^.

Studies measuring small numbers of miRNAs have shown their presence in circulating blood; specifically in platelets ^[@ref-9]^, plasma ^[@ref-10]^, and mononuclear cells ^[@ref-11]^. In studies examining specific miRNAs ^[@ref-12],\ [@ref-13]^, differential expression was noted both in hematopoietic cell lines ^[@ref-13]^ and between human and mouse cells ^[@ref-12]^. Interestingly, miRNAs have been detected in cell-free human plasma preparations ^[@ref-14]^. They have been found to be stable and protected from endogenous RNase activity ^[@ref-14]^. In addition, levels of a specific miRNA ( *miR-141*) can distinguish patients with prostate cancer from healthy controls ^[@ref-14]^.

Basic studies have shown that miRNAs regulate cardiac differentiation, angiogenesis, and myocyte growth ^[@ref-15],\ [@ref-16]^. Small clinical studies have also shown that levels of specific miRNA have been correlated with myocardial infarction in cardiac tissue from humans ^[@ref-17]^ and animal models ^[@ref-18],\ [@ref-19]^. A recent study examined one miRNA ( *miR-1*) from plasma and related it to acute myocardial infarction ^[@ref-10]^. In stable and unstable coronary artery disease patients, 157 miRNAs were measured from peripheral blood mononuclear cells and differential expression was found ^[@ref-11]^.

As shown by these studies, there are some publications about circulating miRNAs in cardiovascular disease ^[@ref-9],\ [@ref-20]^. In addition, the existing studies are restricted by incomplete evaluation of currently known miRNAs. Available arrays are constrained by incomplete miRNA coverage, issues in discriminating between closely related miRNAs, as well as ongoing discovery of new miRNAs (and the inherent lack of flexibility of the array platform). In addition, miRNA arrays have poor reproducibility when across clinical populations or in larger samples sizes ^[@ref-21]^. We have developed a combined method of miScript miRNA assays (Qiagen, Germantown, MD) and Dynamic Arrays (Fluidigm, South San Francisco, CA) that employs quantitative RT-PCR (qRT-PCR) using a high-throughput process that allows us to analyze more samples vs. more miRNAs in a very short time ^[@ref-22]^. Lastly, unlike hybridization-based microarray profiling techniques, qRT-PCR is considered the gold standard for RNA expression and does not require further confirmation analysis. Using this platform, a complete analysis of circulating whole blood, cellular, and cell-free miRNA was performed. The relevance of these findings to coronary disease was determined by measuring plasma miRNA expression in patients presenting for coronary angiography. The findings suggest that the distinct patterns of miRNA expression in components of whole blood may reflect specific patterns of disease.

Results
=======

miRNA Profile in Human Plasma, Serum, Platelets, Mononuclear Cells and Whole Blood
----------------------------------------------------------------------------------

There is minimal information defining miRNA expression in human blood and a complete screen of all known miRNAs has never been reported due to the limitations of current arrays and the cost of extensive qRT-PCR screening. Using blood samples from normal subjects and high-throughput qRT-PCR, the miRNA expression profile was determined for whole blood, isolated platelets, mononuclear cells, plasma and serum from five healthy subjects. Of the 852 miRNAs measured [(Supplemental Table 1)](#ST1){ref-type="other"}, the distribution of circulating miRNA that were most abundantly expressed in plasma and many of the blood derived sources is shown in [Table 1](#T1){ref-type="table"}. Gene expression is listed as cycle threshold value (Ct) consistent with RT-PCR-based data. Because the Ct values are listed, higher gene expression is reflected by a lower number. A complete list of miRNA expression for all sources is shown in [Supplemental Table 2](#ST2){ref-type="other"} (mean Ct value) and [Supplemental Table 3](#ST3){ref-type="other"} (mean delta Ct, accounting for housekeeping gene hsa-RNU1A-1). Unlike mRNA expression, it is currently unclear if miRNA data is more reliable when normalized with a housekeeping gene. This is especially germane for the cell-free plasma samples where a fixed volume was used and gene expression does not need to be normalized for cell count.

###### Expression of miRNAs from whole blood, isolated platelets, mononuclear cells, plasma, and serum from healthy subjects (mean Ct values has shown; higher value indicates lower expression).

  **miRNA Name**    **Plasma**   **PBMCs**   **Platelets**   **Whole Blood**   **Serum**
  ----------------- ------------ ----------- --------------- ----------------- -----------
  hsa-miR-1234      14.68        14.13       13.34           15.08             13.22
  hsa-miR-641       15.20        14.66       14.43           15.08             15.50
  hsa-miR-124a      15.63        17.54       17.25           18.59             18.25
  hsa-miR-933       15.64        12.37       13.99           12.30             14.66
  hsa-miR-7-2\*     15.87        16.30       17.58           16.42             18.38
  hsa-miR-323-3p    16.53        15.06       15.26           15.08             15.51
  hsa-miR-631       17.34        15.96       16.43           16.43             17.01
  hsa-miR-566       17.81        15.56       19.99           15.47             17.36
  hsa-miR-1185      17.97        N/A         N/A             N/A               N/A
  hsa-miR-766       17.98        13.70       15.76           13.94             16.55
  hsa-miR-625\*     18.03        20.71       19.75           20.90             18.80
  hsa-miR-1228      18.06        14.63       17.15           16.36             18.07
  hsa-miR-628       18.17        18.10       17.29           18.13             17.71
  hsa-miR-601       18.38        15.22       17.46           15.73             18.85
  hsa-miR-1281      18.78        16.72       16.65           16.75             17.14
  hsa-miR-636       18.94        15.46       17.50           15.47             18.54
  hsa-miR-657       19.04        19.11       17.50           19.39             18.50
  hsa-miR-33b\*     19.48        18.82       21.05           18.80             20.59
  hsa-miR-553       19.51        N/A         N/A             N/A               N/A
  hsa-miR-148a\*    19.76        17.90       20.00           18.05             20.47
  hsa-miR-637       20.09        17.88       18.08           18.25             19.65
  hsa-miR-375       20.24        18.52       18.99           17.80             19.35
  hsa-miR-129-3p    20.24        20.78       20.18           20.44             20.57
  hsa-miR-99b       20.31        17.33       19.18           18.73             19.49
  hsa-miR-380-5p    20.33        15.62       17.80           16.05             18.00
  hsa-miR-508-5p    20.36        23.27       N/A             24.04             N/A
  hsa-miR-1178      20.36        21.76       20.42           23.43             20.10
  hsa-miR-92a       20.54        12.14       12.23           8.94              20.42
  hsa-miR-888       20.55        20.25       18.76           20.30             18.72
  hsa-miR-525\*     20.59        24.62       N/A             N/A               N/A
  hsa-miR-875-3p    20.63        18.91       20.36           18.98             20.64
  hsa-miR-876-5p    20.64        20.37       22.90           21.25             20.37
  hsa-miR-630       20.74        18.22       18.06           18.55             21.05
  hsa-miR-519e      20.79        24.38       N/A             24.63             N/A
  hsa-miR-632       20.84        16.96       19.90           17.08             20.58
  hsa-miR-1301      20.86        19.18       19.74           19.85             20.22
  hsa-miR-654       20.87        16.66       19.45           16.88             19.89
  hsa-miR-548a-5p   20.90        N/A         N/A             N/A               N/A
  hsa-miR-877\*     21.16        19.21       21.59           19.60             21.38
  GAPDH             21.17        14.52       17.52           15.06             22.86

miRNA results and demographic data.miRNA results and demographic data.Click here for additional data file.

List of all miRNA assays.All miRNAs measured in whole blood, platelets, peripheral blood mononuclear cells (PBMCs) and plasma.Click here for additional data file.

Unique distribution of miRNAs expressed in plasma, peripheral blood mononuclear cells (PBMCs), platelets, whole blood and serum. Average Ct values shown.Expression of miRNA measured in whole blood, platelets, peripheral blood mononuclear cells (PBMCs) and plasma. Ct value, higher number indicates lower expression.Click here for additional data file.

Unique distribution of miRNAs expressed in plasma, peripheral blood mononuclear cells (PBMCs), platelets, whole blood and serum. Average delta Ct values shown, housekeeping gene Hs-RNU1A-1 used to calculate delta Ct.Quantitative expression of miRNA measured in whole blood, platelets, peripheral blood mononuclear cells (PBMCs) and plasma. Delta Ct value; values have been normalized using the housekeeping miRNA U44.Click here for additional data file.

###### Expression of plasma miRNAs in patients with ≥ 70% CAD, patients with ≤ 70% CAD, and normal arteries. Data are expressed as mean delta Cts and standard deviation.

Expression of plasma miRNAs in patients with 1) ≥70% CAD, 2) patients with

###### 

Click here for additional data file.

One-hundred and ninety four miRNAs were not expressed in any of the blood-based samples. Peripheral blood mononuclear cells (PBMCs) contained the highest number of miRNAs (658) followed by whole blood (609), platelets (448), serum (178) and plasma (147). As the abbreviated list shown in [Table 1](#T1){ref-type="table"} demonstrates, while there is consistency between the groups, some miRNAs are more highly expressed in select sources. Sixty miRNAs were expressed in all five components. As the precise source of miRNA in plasma is not yet known, there was particular interest in comparing the expression between plasma and cellular miRNA patterns. Based on the significant overlap between the groups, it is difficult to determine the source for many of the specific plasma-derived miRNAs. It is not clear from the current data which miRNAs have a non-blood-based cellular source. Interestingly, miR-1185 and miR-548a-5p were much more abundantly expressed in plasma as compared to PBMCs or platelets, or only expressed in plasma. Although an interesting observation, the source of these two miRNAs cannot be determined from this data. In addition, some genes were expressed in platelets or PBMCs and not whole blood. This is likely due to the greater dilution used with PAXgene tubes and the loss of measurable expression of less abundant miRNAs.

Plasma miRNA expression in patients with and without significant coronary disease
---------------------------------------------------------------------------------

The initial hypothesis of this study was that patients with significant coronary disease would have altered expression of plasma miRNA. Patients were divided into two groups [(Table 2)](#T2){ref-type="table"}; 1) ≥70% coronary stenosis of any coronary artery or 2) \<70 coronary stenosis. There were notable differences in expression of some of the miRNAs between these two groups [(Table 3)](#T3){ref-type="table"}. By direct comparison, several plasma miRNAs were found to have over 2-fold increased expression in patients with significant coronary disease (≥70%) as compared to those with minimal coronary disease or normal coronary arteries [(Figure 1)](#f1){ref-type="fig"}. Initial statistical analysis demonstrated that anti-hypertensive therapy, smoking, and lipid lowering therapy have a positive association with coronary artery status [(Table 2)](#T2){ref-type="table"}. Increased expression of miR-494, miR-769-3p and miR-490-3p was associated with ≥70% coronary stenosis. Next, the six variables were fit into a logistic regression analysis. As seen in [Table 4](#T4){ref-type="table"}, anti-hypertensive therapy, smoking and miR-769-3p were significantly associated with the coronary status.

###### Characteristics of catheterization sample participants.

Continuous measures, mean ± S.D., or number and percent with stated characteristic.

  ------------------------------------------------------------------------------------------
                      **Non CAD**\                **CAD**\                           
                      **Group (\<70 CAD) n 49**   **Group (≥70 CAD) n 34**           
  ------------------- --------------------------- -------------------------- ------- -------
  Age                 56.2                        11.3                       61.3    10.6

  Male                28.0                                                   27.0    

  Female              22.0                                                   7.0     

  Hypertension        21                                                     27      

  Smoking             8                                                      19      

  Lipid Treatment     6                                                      16      

  Diabetes            10                                                     7       

  Family History      14                                                     11      

  Antihypertensive\   13                                                     28      
  Therapy                                                                            

  Hormone\            13                                                     10      
  Replacement\                                                                       
  Therapy                                                                            

  Glucose             129.3                       71.3                       135.1   76.2

  Total Cholesterol   169.9                       36.6                       168.4   40.5

  HDL                 39.5                        8.8                        36.5    12.5

  LDL                 99.2                        29.5                       94.4    34.0

  Triglyceride        171.6                       108.2                      182.6   100.4
  ------------------------------------------------------------------------------------------

###### Expression of plasma miRNAs in patients with ≥70% CAD as compared to patients with \<70% CAD or normal arteries.

Data is expressed as the mean delta Ct (Normalized to the RNU1A) and standard deviation. A lower number indicates increased miRNA expression. Bold valuesones are associated with CAD. More explanation in [Table 5](#T5){ref-type="table"}.

                       **Non CAD Group**   **CAD Group**              
  -------------------- ------------------- --------------- ---------- ----------
  hsa-miR-127          4.50                1.47            3.76       1.81
  hsa-miR-129-3p       5.83                1.25            4.99       1.86
  hsa-miR-532-3p       4.92                1.74            4.07       2.12
  hsa-miR-433          5.65                1.32            4.90       1.80
  **hsa-miR-494**      **5.12**            **1.32**        **4.11**   **2.16**
  hsa-miR-375          -1.71               1.52            -2.64      1.99
  hsa-miR-449          7.15                1.55            6.64       1.91
  hsa-miR-323-3p       -7.48               2.21            -8.05      1.94
  hsa-miR-1207-5p      5.00                2.30            4.08       2.61
  hsa-miR-615-5p       5.02                1.23            4.25       1.74
  hsa-miR-532          4.85                1.74            4.12       2.25
  hsa-miR-99b          -1.83               1.31            -2.64      1.99
  hsa-miR-1180         5.25                1.47            4.41       1.73
  hsa-miR-1224-5p      5.12                4.32            4.76       2.72
  hsa-miR-574          5.01                1.50            4.33       2.02
  hsa-miR-92a          6.54                1.93            5.64       2.16
  hsa-miR-1183         7.32                4.91            6.05       5.59
  hsa-miR-92b          5.18                1.68            4.26       1.92
  **hsa-miR-490-3p**   **3.34**            **1.33**        **2.13**   **2.02**
  hsa-miR-1253         4.14                3.64            4.10       1.94
  hsa-miR-1273         3.28                3.99            2.12       3.26
  hsa-miR-1301         0.66                3.21            0.68       1.97
  hsa-miR-1972         3.91                2.00            3.01       2.16
  hsa-miR-345          3.91                1.52            3.29       2.07
  hsa-miR-383          5.78                0.61            5.35       1.46
  hsa-miR-489          -0.37               1.14            -0.62      1.29
  hsa-miR-202          2.82                0.65            2.67       1.19
  hsa-miR-373          3.98                0.53            3.76       1.15
  hsa-miR-220          2.45                1.55            1.86       2.09
  hsa-miR-320a         4.11                1.02            4.03       0.98
  hsa-miR-432          4.25                0.86            4.11       0.98
  hsa-miR-483-3p       3.57                0.46            2.66       5.67
  hsa-miR-339-3p       5.15                0.73            4.82       1.19
  hsa-miR-483-5p       -1.29               0.52            -1.35      0.61
  hsa-miR-487a         4.35                0.45            4.10       1.00
  hsa-miR-548b-5p      5.40                1.74            4.44       2.66
  hsa-miR-502          1.56                1.20            0.89       1.94
  hsa-miR-631          -3.98               1.63            -4.52      2.06
  hsa-miR-555          1.81                1.62            1.29       2.00
  hsa-miR-641          -5.04               1.91            -5.82      2.44
  hsa-miR-566          5.56                1.78            4.80       2.13
  hsa-miR-628          1.36                1.63            0.75       1.94
  hsa-miR-585          5.60                1.85            4.51       2.55
  hsa-miR-637          -1.81               1.65            -2.37      2.03
  hsa-miR-767-3p       4.32                1.57            3.91       1.80
  **hsa-miR-769-3p**   **4.39**            **2.96**        **2.61**   **3.42**
  hsa-let-7b           4.43                8.29            4.25       4.00
  hsa-miR-1914         4.80                4.82            5.45       2.41
  hsa-miR-149          4.40                5.51            4.75       2.40
  hsa-miR-150          2.04                2.85            0.51       2.70
  hsa-miR-33b          0.87                2.02            -0.07      2.22
  hsa-miR-7            -3.73               1.84            -4.87      3.82

![Fold change in plasma miRNA expression between in two groups.\
miRNAs shown had expression increased \>2-fold between the groups; 1) ≥70% coronary stenosis of any coronary artery or 2) \< 70 coronary stenosis.](f1000research-1-221-g0000){#f1}

###### Logistic regression analysis using demographic characteristics and significantly differentially expressed miRNAs.

  --------------------------------------------------------------------------------------
                             **Estimate**   **Std.**\   **z value**   **Pr (\>\|z\|)**
                                            **Error**                 
  -------------------------- -------------- ----------- ------------- ------------------
  (Intercept)                -1.63          1.12        -1.44         0.14

  Antihypertensive Therapy   2.86           0.77        3.70          0.000213 \*\*\*

  Smoking                    2.44           0.77        3.16          0.001568 \*\*

  Lipid Lowering Therapy     0.74           0.73        1.01          0.30

  hsa-miR-494                0.05           0.27        0.20          0.83

  hsa-miR-490-3p             -0.30          0.31        -0.96         0.33

  hsa-miR-769-3p             -0.23          0.11        -1.98         0.047044 \*
  --------------------------------------------------------------------------------------

Plasma miRNA expression: significant coronary disease vs. disease-free
----------------------------------------------------------------------

We initially determined whether presence of significant coronary disease, as defined by ≥70% stenosis is associated with specific miRNA expression. A secondary question is whether presence/absence of coronary disease is associated with miRNA expression. To study this, patients were placed into one of three groups; 1) patients with CAD; at least one of the coronary arteries have ≥70% occlusion; 2) patients with minimal CAD; coronary occlusion 1%--\<70%; and 3) coronary atherosclerosis-free, patients with no angiographically documented coronary artery stenosis. Because the numbers are small, a simple (non-statistical) comparison was made to determine trends. As seen in [Figure 2](#f2){ref-type="fig"} and [supplemental table 4](#ST4){ref-type="other"}, 18 miRNAs had a varied expression pattern between group 1 and group 3. Seventeen miRNAs were upregulated at least 2-fold with only miR-1914 downregulated 0.5-fold. Interestingly, most miRNAs demonstrated a dose response with the greatest expression in patients with the most coronary disease and the least expression in disease-free patients [(Supplemental table 4)](#ST4){ref-type="other"}.

![Fold change in plasma miRNA expression between three groups.\
miRNAs shown had expression increased \>2-fold or decreased \<0.5-fold for the groups; 1) patients with CAD; at least one of the coronary arteries have ≥70% occlusion; 2) patients with atherosclerosis but not clinically significant CAD; coronary occlusion 1%--\<70%; and 3) coronary atherosclerosis-free, patients with no angiographically documented coronary artery stenosis.](f1000research-1-221-g0001){#f2}

miRNA target predictions
------------------------

Currently, the capacity to measure miRNAs far outpaces our ability to understand their function in a given tissue. However, to better understand the potential significance of our findings, we conducted analyses that predict targets of the miRNAs that were up- or downregulated in coronary disease using two methods; current publications ( [www.ncbi.nlm.nih.gov/pubmed/](www.ncbi.nlm.nih.gov/pubmed/)) and TARGETSCAN 5.1 ( [www.targetscan.org](www.targetscan.org)). Using these methods, results for miRNA targets varied between 3 to 369 targets per miRNA when identified. With the TARGETSCAN search, target genes for individual miRNAs were identified using the context score for specific sites within genes. The context score is the sum of site-type contribution, 3' pairing contribution, local AU contribution, and position contribution. The lower the context score indicates the most highly predicted targets for each miRNA. By TARGETSCAN search, miRNAs miR-1914 and miR-7-2, had no target gene identified.

Detailed predictions for the miRNAs found to be significant in CAD are shown in [Table 5](#T5){ref-type="table"}. In broad terms, some miRNAs appear to target transcription factors, growth factors, cytokine regulation, transmembrane proteins, signal transduction pathways, and epigenetic pathways such as histone acetylases. Prediction results for specific miRNAs in TARGETSCAN include the following: miR-129-3p and miR-494 target HMGCS1; miR-150 targets MMP14; miR-150, and 92b target MMP16. Additionally, miR-1207 appears to target energy metabolism (most likely involving glucose metabolism).

###### MiRNA predictions for target genes associated with significant coronary disease using TARGETSCAN.

Individual miRNAs target genes identified as significantly different between patients with and without significant coronary disease were selecting using the context score, a sum of; site-type contribution, 3' pairing contribution, local AU contribution, and position contribution. The lowest scores show highest predictions.

  **Target gene**        **Gene name/miRNA Name**                                                                      **Total Context Score**
  ---------------------- --------------------------------------------------------------------------------------------- -------------------------
  **hsa-miR-494\***                                                                                                    
  SOCS6                  Suppressor of cytokine signaling 6                                                            -1.06
  HMGCS1                 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)                                    -0.88
  COL6A6                 Collagen type VI alpha 6                                                                      -0.64
  BCAP29                 B-cell receptor-associated protein 29                                                         -0.53
  SCARB2                 Scavenger receptor class B, member 2                                                          -0.52
  IGF1R                  Insulin-like growth factor 1 receptor                                                         -0.31
  F11R                   F11 receptor                                                                                  -0.41
  **hsa-miR-490-3p\***                                                                                                 
  LEP                    Leptin                                                                                        -0.32
  IL1RAP                 Interleukin 1 receptor accessory protein                                                      -0.31
  CD63                   CD63 molecule                                                                                 -0.29
  TGFBR1                 Transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kDa)   -0.21
  ADIPOR2                Adiponectin receptor 2                                                                        -0.2
  MEF2D                  Myocyte enhancer factor 2D                                                                    0
  **hsa-miR-769-3p\***                                                                                                 
  FAM130A1               Family with sequence similarity 130, member A1                                                -0.4
  SHPK                   Sedoheptulokinase                                                                             -0.39
  KCNA5                  Potassium voltage-gated channel, shaker-related subfamily, member 5                           -0.35
  MARCKS                 Myristoylated alanine-rich protein kinase C substrate                                         -0.25
  PBRM1                  Polybromo 1                                                                                   -0.24
  ISOC2                  Isochorismatase domain containing 2                                                           -0.23
  MYCL1                  V-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma derived (avian)               -0.23
  KPNA6                  Karyopherin alpha 6 (importin alpha 7)                                                        -0.2
  KDSR                   3-ketodihydrosphingosine reductase                                                            -0.17
  COLEC12                Collectin sub-family member 12                                                                -0.15
  TSPAN1                 Tetraspanin 1                                                                                 -0.15
  PIM2                   Pim-2 oncogene                                                                                -0.11
  KIAA1128               Family with sequence similarity 190, member B (FAM190B)                                       -0.07

We also analyzed the miRNAs that were unique to plasma, miR-1185-1 and miR-548a-5p-1. While many potential targets were identified, these miRNAs were predicted to target genes involved in controlling transcription factors, as well as several growth and cell cycle components.

Discussion
==========

MicroRNAs (miRNAs) are short regulatory RNAs that participatein the control of approximately 30% of all protein-coding genes ^[@ref-4]--\ [@ref-6]^. The expressionof many miRNAs is usually specific to a tissue or developmentalstage, and the miRNA expression pattern is altered during theprogression of several diseases ^[@ref-7],\ [@ref-8]^. Most miRNAs are transcribed by RNA polymerase II from individual miRNA genes, from introns of protein coding genes, or from polycistronic transcripts that often encode multiple related miRNAs ^[@ref-4],\ [@ref-23]^. Although miRNAscan guide mRNA cleavage, the basic function of miRNA is to mediateinhibition of protein translation ^[@ref-1],\ [@ref-7],\ [@ref-24]--\ [@ref-27]^ through miRNA-inducedsilencing complexes (miRISCs). The guiding strand of miRNA ina miRISC interacts with a complementary sequence in the 3'-untranslatedregion (3'-UTR) of its target mRNA by partial sequence complementarities, resulting in translational inhibition ^[@ref-1],\ [@ref-7]^.

In this study, the distribution of miRNA expression in whole blood, platelets, PBMCs plasma and serum showed significant overlap. Of particular interest are the nucleus-lacking platelet and the cell-free plasma expression levels. A primary question is why platelets would have miRNA? Platelets are produced in the bone marrow from megakaryocytes as cytoplasmic fragments without genomic DNA ^[@ref-28]^. Platelets, however, retain a small amount of megakaryocyte-derived messenger RNAs (mRNAs) that have recently been suggested to be of physiological significance. Platelets can respond to physiological stimuli at the levels of protein translation and mRNA splicing ^[@ref-29],\ [@ref-30]^. There are few published studies describing platelet miRNAs ^[@ref-13]^. In this study, cells of hematopoietic lineage were described to have a limited number of miRNAs (this study only tested for 19 miRNAs) and functionality was not shown. Interestingly, our data demonstrate that platelets express nearly the same number of miRNAs as PBMCs. The number of miRNAs in PBMCs is slightly less than in whole blood with the reason likely being dilution of low abundant PBMC miRNAs in whole blood.

In limited numbers, miRNAs have been detected in cell-free human plasma preparations ^[@ref-14]^. They have been found to be stable and protected from endogenous RNase activity ^[@ref-14]^. In addition, levels of a specific miRNA ( *miR-141*) can distinguish patients with prostate cancer from healthy controls. In our analysis, we found moderate to high levels of expression of miRNAs in plasma in both normal subjects and patients with coronary disease, albeit in lower numbers as compared to platelets and PBMCs. What these data do not provide is the specific source of circulating miRNAs. This is a fundamental and fascinating question. They are believed to arise from three potential mechanisms: apoptosis, cellular activation with release of protrusions, and microsome/microvesicle formation. For example, Mitchell et al. found miR-141 differentially expressed in plasma in microsomes of prostate cancer patients ^[@ref-14]^. It is possible that the miRNAs detected by our measurements in plasma or blood could be derived from endothelial cells or the atherosclerotic plaque itself. Further fundamental experiments are needed to answer this question. Recently, it has been shown that HDL particles deliver miRNAs ^[@ref-31]^. Additionally, Wang et al. reported that plasma and whole blood miR-133 and miR-328 levels are increased in AMI patients ^[@ref-32]^.

By the current data, we cannot assign precise punitive targets; however, specific bioinformatics approaches have been developed to predict miRNAs present in the genome of different organisms. These techniques are based on the observation that transcripts are usually highly conserved between related species and produced from precursor transcripts of similar size and structure. Using these bioinformatics approaches and the limited information available in the literature, we assembled potential target genes for the miRNAs expressed in significantly different amounts between patients with and without ≥70% coronary disease [(Table 5)](#T5){ref-type="table"}. The list included a diverse range of functional and structural genes. This includes leukocyte and platelet recruitment to the atherosclerotic tissues, matrix reorganization, foam cell formation, growth/proliferation, and angiogenesis. However, these predictions do not provide definitive targets and additional basic studies are needed to provide clearer mechanistic information.

Also unique to our study is the specific method of measurement we used, which allowed for flexibility in adding newly discovered miRNAs, the use of small volumes, and high-throughput methods for qRT-PCR. Currently, there are several miRNA microarray products available that measure fewer miRNAs and some consist of older versions of the Sanger miRBase Sequence Database. Using the universal cDNA reaction feature of miScript provided the ability to profile all miRNAs with one cDNA reaction. Unlike the hybridization-based microarray profiling techniques, by coupling the miScript and Biomark Systems, confirmation analysis was not required for individual miRNAs. However, there are important limitations of our study. Despite the expansive miRNA survey for blood components, we cannot define the specific source for the plasma miRNA nor its eventual destination. Our study of coronary patients was limited by only being able to evaluate plasma miRNA, as other blood components were not available to us. In addition, while the miRNA data provided from these patients are unique, the numbers are still small making further analysis based on any subgroup statistically unfeasible.

In summary, miRNAs are small RNAs that play an important role in the negative regulation of gene expression by suppressing protein translation and have been detected in cell-free plasma and have been related to select diseases. By examining all measurable miRNAs, we defined the relative expression in blood components and find significant expression in platelets, PBMCs, whole blood, plasma and serum. By comparing plasma miRNA expression in patients with coronary disease, we begin to define specific miRNAs that are altered and provide potential targets that influence atherosclerosis.

Materials and methods
=====================

Sample procurement
------------------

This study was approved by Mersin University Ethical Committee (06/05/2009, \#6/144) and written consent was obtained from the subjects to test the hypothesis of whether coronary occlusion of ≥70% is associated with increased plasma miRNA expression levels. Upon enrollment, a study coordinator identified the presence of the following risk factors: (1) age, (2) male sex, (3) clinical history of diabetes, (4) clinical history of hypertension, (5) cigarette smoking, (6) clinical history of hypercholesterolemias, and (7) family history of coronary disease. Coronary angiograms were analyzed off-line in a blinded fashion with the use of digital calipers to measure stenosis severity, and stenosis was defined as a dichotomous variable: if a stenotic lesion was ≥70%, that vessel was counted as stenosed. The presence or absence of stenotic disease was also noted. Patients were ranked as having 0- to 3-vessel disease (number of coronary arteries with detectable atherosclerotic disease). For each patient, K ~3~EDTA arterial blood (5 mL) was collected just prior to coronary angiography. Blood samples were centrifuged (3,000 g) and 400 µl plasma samples were stored at -80°C until RNA isolation.

In a separate smaller study, blood was obtained from healthy consented volunteers (n=5; 3 female, 2 male, average age=45) at Boston University School of Medicine as previously described ^[@ref-33]^. The study was approved by Boston University IRB and written consent obtained from the subjects. All subjects were free of medications or supplements, and had no history of hypertension, diabetes, smoking, or hyperlipidemia. Blood was collected into PAXgene RNA tubes (Becton Dickinson, Franklin Lakes, NJ) for whole blood, into CPT tubes (Becton Dickinson) for peripheral blood mononuclear cells (PBMCs), into citrate tubes for platelets and plasma, and empty tubes for serum. Isolated platelets were prepared as previously described.

**RNA isolation:** Total RNA including miRNAs was isolated from 200 µl plasma samples using miRVana Paris Kit (Ambion, Austin, TX). The RNA samples were stored at -80°C until cDNA conversion.

**cDNA conversion:** Isolated RNA samples were converted to cDNA using miScript Reverse Transcription Kit (Qiagen, Germantown, MD). The RNA was converted to cDNA using the following conditions: 37°C for 60 min, 95°C for 5 min, and 4°C hold until further processing or storage. cDNA samples were kept at -80°C until PCR analysis.

**Pre-amplification:** Prior to PCR, cDNA samples were pre-amplified using Taqman PreAmp Master Mix (Applied Biosystems, Foster City, CA). PreAmp Master Mix and 0.2x Primers were added to the cDNA samples and pre-amplified as follows: 95°C for 10 min once, 95°C for 15 sec, 55°C for 30 sec, 70°C for 4 min (final three steps repeated for 14 cycles).

**qRT-PCR:** Quantitative Real-Time PCR reactions (qRT-PCR) were performed using the high-throughput BioMark Real-Time PCR system (Fluidigm, South San Francisco, CA). Pre-amplified cDNA samples were diluted with 0.1mM EDTA in TE Buffer (1:5) and mixed with Power Sybr Green PCR Master Mix (Applied Biosystems), AmpliTaq Gold DNA Polymerase (Applied Biosystems) and Sample Loading Reagent (Fluidigm), then pipetted into sample inlets of Dynamic Array 96.96 chips (Fluidigm). Assay Loading Reagent (Fluidigm) and primers (Qiagen) were mixed and pipetted into assay inlets of Dynamic Array 96.96 chips. The IFC Controller HX (Fluidigm) was used to distribute primers and samples into chip reaction wells for qRT-PCR by microfluidic delivery. Gene expression experiments performed at Mersin and Gaziantep Universities in Turkey. The data were normalized using RNU1A1. Coefficient variations were less than 10% for almost all of the assays. Plasma volumes for all samples were constant (200 µl) and all following steps such as cDNA, PreAmplification and qRT-PCR had the same volumes always for all samples.

Statistics
----------

When examining miRNAs that had larger fold changes between the CAD groups ( [Figure 1](#f1){ref-type="fig"} and [Figure 2](#f2){ref-type="fig"}) and those more highly expressed in the circulation using similar bioinformatics methods (such as targetscan), there were many miRNA targets that are known to control the processes important in the development of atherosclerosis (list not shown).

Univariate and bivariate analysis
---------------------------------

We initially summarized our data in different stratifications based on our outcome variables (coronary disease status). Next, we examined the bivariate relationship between the response variable and quantitative covariates using either two-sample t-test or Kruskal-Wallis test, where appropriate. Specifically, the t-test was conducted to test for a mean difference in quantitative demographic variables and miRNA expression level between two categories of coronary disease status. The pooled variance or the Satterthwaite's method was used to estimate variance based on the equality of variance test. We employed Kruskal-Wallis test to determine whether there was any mean difference among groups in the scenario with three-category outcome variable.

Multivariate analysis
---------------------

Tree-based methods have been increasingly applied to biological research such as microarray data analysis and genome-wide association studies ^[@ref-34],\ [@ref-35]^. RandomForest is a flexible nonparametric approach, which consists of many decision trees from bootstrap samples. In this study, we constructed randomForest ^[@ref-25]^ in identifying relevant variables to our outcome variable using the randomForest package in R (2.10.1) ^[@ref-36]^. Furthermore, we also conducted logistic regression and multinomial logistic regression where appropriate ^[@ref-37]^.
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